Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Fiven ASA second quarter report 2022

· Total revenues reported at EUR 50.8m representing an increase of 68.1% versus Q2 2021 and sequential increase of 1.1% over Q1 2022 · The adjusted EBITDA was EUR 15.2m, versus EUR 5.8m in Q2 2021 and EUR 11.9m in Q1 2022. · Fiven results are impacted by strong demand, higher market shares and inflationary market prices · The price increase is compensating for power and raw material inflation as well as rising transportation costs and labor costs · The higher market share is following shortage of SiC due to supply chain turbulences and competitors reducing their output ·

Scandinavian ChemoTech's subsidiary Vetiqure AB signs agreement with a German AniCura clinic for participation in a study

As previously communicated, Vetiqure AB and three of AniCura's clinics have a collaboration agreement regarding TSE treatment of soft tissue sarcoma in dogs. This agreement is now being updated with a clinic in Germany.Due to the high workload at AniCura Animal Hospital Albano in Stockholm, which was one of the Swedish clinics that would have participated in the study, a mutual decision has been made between the parties to move the study from this clinic.   As a replacement, Vetiqure, in consultation with AniCura, has identified Dr Ramona Maier, one of the group's most well-known

INVISIO receives a second volume order for its Intercom system

INVISIO is receiving another volume order for the Intercom System, within a short period of time. The customer is the same European NATO country that placed a first order for the solution in July 2022. The new order is valued at SEK 14 million. This is one more significant reference order for the new Intercom system. INVISIO estimates that the future needs of the customer may lead to further volume orders. The systems are to be delivered in the third and fourth quarter of 2022 and the combined value is SEK 14 million. “It is very gratifying that the customer now places a second

Sports coaching graduate scores top marks

A graduate who never planned to go to university has achieved a first-class degree and the highest academic award on her course.Olivia Taylor, 21, from Cannock, studied BSc (Hons) Physical Education and Youth Sport Coaching  at Staffordshire University after being inspired by a lecturer at college. She explained: “I never really thought going to university was achievable for me during high school, as I won’t lie, I hated it – I always doubted my academic ability and relied on my sporting genes. “It was Jack Bullock,

CS MEDICA A/S invites to a live-streamed Q&A Event on September 2th at 14:00 – 14:30 CEST

CS MEDICA A/S (“CS MEDICA” or the “Company”) announces today that the company invites investors, brokers, analysts, and media to a live-streamed Event Friday the 2th of September at 14:00 CEST.CS MEDICA is currently receiving a lot of questions regarding the latest press releases and to elaborate and answer these question, a webinar will be conducted Friday the 2nd of September between 14:00 – 14:30 CST.  The event will be held in English. Questions can be asked prior to the event by sending an email to info@cs-medica.com or during the webcast via a chat function. Questions should be

Embracer Group completes acquisition of Crystal Dynamics, Eidos-Montréal, Square Enix Montréal amongst other assets

On 2 May 2022, Embracer Group AB ("Embracer") entered into an agreement to acquire the development studios Crystal Dynamics, Eidos-Montréal, Square Enix Montréal, and a catalog of IPs including Tomb Raider, Deus Ex, Thief, Legacy of Kain and more than 50 back-catalog games from SQUARE ENIX HOLDINGS CO., LTD.All conditions for the transaction, including regulatory approvals, have now been fulfilled and the transaction may be completed. Embracer has, therefore, today completed the acquisition. The companies will form the 12th operative group under the leadership of Phil Rogers and his

Resolutions of Extraordinary Annual General Meeting in SameSystem A/S

Company Announcement No. 20-2022Copenhagen, 26 August 2022 The Extraordinary Annual General Meeting of SameSystem A/S took place on August 26, 2022, at SameSystem A/S, Rentemestervej 2A, 2400 København NV, in accordance with the agenda. Søren Elmann Ingerslev, was elected chairman of the meeting. Carsten Fensholt, Lars Mathiesen and Tommy Holte were elected as members of the board. In continuation of the general meeting, the board of directors constituted itself with Carsten Fensholt as chairman of the board of directors.The minute of the Annual General Meeting is available at

Elkem ASA – Exercise of share options under share incentive programme

Oslo, 26 August 2022 Option holders under Elkem ASA's ("Elkem" or the "Company", OSE ticker code: "ELK") share incentive programme have today exercised a total of 2,344,981 options, of which 807,670 options have an exercise price of NOK 19.10 per share, 775,345 options have an exercise price of NOK 23.53 per share, 661,966 options have an exercise price of NOK 31.20 per share, and 100,000 options have an exercise price of NOK 38.52 per share. The exercised options will be settled by delivery of Elkem’s shareholding of own shares. Following the transfer, the Company will hold 6,340,019

Success when ElEcoRunner was demonstrated - planning for market introduction begins

During Friday, August 26, together with our project partner the Swedish Sea Rescue Society, a planned demonstration and tests with the ElEcoRunner were carried out. The result was beyond expectations - the future is fossil-free and 100% electric.The company management set a clear goal earlier this year: that the company would be able to demonstrate the new version, named ElecoRunner Zero Series (EZS), by August 26 at the latest. Together with invited representatives from the Swedish Sea Rescue Society and the development team, a demonstration and tests were carried out that pave the way for

EAB Group Plc’s Board of Directors decided on an extra distribution of dividend in accordance with the combination agreement between EAB Group Plc and Evli Plc

EAB Group Plc, Stock Exchange Release, 26 August 2022, 3:00 p.m. (EET)   EAB Group Plc’s Board of Directors decided on an extra distribution of dividend in accordance with the combination agreement between EAB Group Plc and Evli Plc As permitted under the combination agreement between EAB Group Plc ("EAB") and Evli Plc ("Evli") concerning the merger of the companies, the Board of Directors of EAB has today resolved based on the authorization granted by the company’s Extraordinary General Meeting held on 14 July 2022, that an extra dividend of EUR 0.17 per share will be distributed

Report for the period 1 January – 30 June 2022

1 April–30 June 2022 - Net sales amounted to SEK 4.44 m (2.81) - Net operating income was SEK 1.67 m (0.34) - The operating loss was SEK 17.26 m (8.67) - The loss for the period was SEK 19.84 m (6.95) - Earnings per share before and after dilution were SEK -39.69 (13.90)   1 January–30 June 2022 - Net sales amounted to SEK 8.12 m (5.42) - Net operating income was SEK 1.04 m (-1.21) - The operating loss was SEK 32.37 m (-19.03) - The loss for the period was SEK 37.37 m (-22.39) - Earnings per share before and after dilution were SEK -74.75 (-44.78) -

Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in HusCompagniet's shares

Company announcement 35/2022 Pursuant to the Market Abuse Regulation article 19, HusCompagniet A/S, CVR no. 36972963 ("HusCompagniet" or the “Company”), shall hereby notify receipt of information of the following transactions made by persons discharging managerial responsibilities in HusCompagniet and persons closely associated with them in HusCompagniet's shares and other financial instruments linked thereto. 1 Details of the Reporting Person and their Closely Associated Personsa) Name Udviklingsselskabet MRN ApS2 Reason for the

AFRY to provide engineering services for Ardagh Group’s new industrial complex in Brazil

Ardagh Group has chosen AFRY to provide engineering and consulting services for the new Ardagh Metal Packaging factory and new Ardagh Glass Packaging factory in Brazil.The assignment includes basic and detailed engineering services as well as supply management of the new multi-line beverage can manufacturing factory, basic engineering services for the glass factory, and environmental impact studies and support for the environmental licensing of the entire complex. Ardagh Group is a global supplier of sustainable and recyclable metal and glass packaging for brand owners around the world.

Karo Intressenter AB publishes supplement to the offer document for the public cash offer to the shareholders of Karo Pharma Aktiebolag

The Offer is not being made, and this press release may not be distributed, directly or indirectly, in or into, nor will any tender of shares be accepted from or on behalf of shareholders in Australia, Hong Kong, Japan, Canada, New Zealand or South Africa, or any other jurisdiction in which the making of the Offer, the distribution of this press release or the acceptance of any tender of shares would contravene applicable laws or regulations or require further offer documents, filings or other measures in addition to those required under Swedish law or otherwise contemplated in connection

Cereno Scientific reports first patient dosed in Phase II study in PAH with drug candidate CS1

Cereno Scientific (XSAT: CRNO B) today announced that the first patient has received their first dose of drug candidate CS1 in the Phase II study in pulmonary arterial hypertension (PAH). Prior to the dosing, the patient has undergone a screening process, implantation of the CardioMEMS HF System to monitor lung pressure during the study, and a full baseline evaluation including a 6-minute walk test, echocardiography, and MRI to enable exploration of CS1’s efficacy. Each patient will undergo a 12-week drug treatment period and a two-week follow-up period. Drug candidate CS1 aims to offer a

Transfer of ownership in First Camp Group and change in the Board of Directors

First Camp Group AB’s (”First Camp Group” or the ”Company”) ultimate main shareholder Norvestor VII L.P., which is managed by Norvestor Investment Management S.a.r.l. (“Norvestor”) has sold its ownership in First Camp Group and certain other portfolio companies to Norvestor SPV II SCSp.Norvestor SPV II SCSp is a continuation fund, managed and advised by Norvestor. Thus, the sale does not constitute a change of ownership (change of control) pursuant to the terms and conditions for the Company’s outstanding bond loan. In connection with the transaction, Tom Sibirzeff has chosen to leave

Brain+’ new digital product for dementia, “CST–Therapist Companion” is ready for commercial launch in Denmark in Q4 2022 – one year ahead of plan

BRAIN+ A/S (BRAINP) · The Brain+ “CST-Therapist Companion” is a new digital product to deliver Cognitive Stimulation Therapy (CST), a globally recognized evidence-based non-pharmaceutical dementia therapy · The Danish market for the Brain+ digital CST products, of which CST-Therapist Companion is the first, is estimated at € 30 million · CST is used in 35 countries today, and Brain+ is the first to offer a digital version of the therapyBrain+ announces that its new digital product, “Cognitive Stimulation Therapy – Therapist Companion” (CST-Therapist Companion) will be launched in

Correction - missing MAR label in earlier press release - I-Tech AB (publ) Interim report Q2 2022

I-Tech AB (publ) (ticker: ITECH) publish the interim report for the second quarter 2022 Click here on the 26 August 2022 at 10:30 to follow the webcast  Click here to go to I-Tech's Financial Reports I-Tech AB (publ) issues a correction to the press release that was published earlier today. The correction refers to the fact that the press release lacked a MAR label with reference to the EU's Market Abuse Regulation (MAR). The following text should have been included in the press release:

Resolutions of EAB Group Plc’s Extraordinary General Meeting

EAB Group Plc, Stock Exchange Release, 26 August 2022, 12:45 p.m. (EET)   Resolutions of EAB Group Plc’s Extraordinary General Meeting   EAB Group Plc’s (“EAB”) Extraordinary General Meeting was held today 26 August 2022 in Helsinki, Finland. The General Meeting resolved to adopt the interim financial statements of the parent company and the consolidated financial statements of the group for the financial period 1 January to 30 June 2022.   EAB GROUP PLCBoard of Directors   Further information:   EAB Group Plc   Daniel Pasternack, CEO+358 50 569 3416

SSAB and POSCO organize a global conference for a greener future

Together for a Green Future! is the slogan for the Hydrogen Iron&Steel Making Forum 2022 in Stockholm this October. It will be hosted by SSAB and South Korean POSCO Group. The focus of the event is to provide a forum where steelmakers can promote collaboration and share advice, ideas and expertise to tackle the global climate change. Registration  Steel plays a critical role in developing industries and building communities. One can say our world is built using steel, which is why it is used in every aspect of our

Danske Hypotek: Interim Report January - June 2022

First half-year in briefJanuary – June 2022 (comparison with January – June 2020 in parentheses)· Operating profit was SEK 501 million (536 million) · Net interest income amounted to SEK 635 million (668 million) · Costs comprised SEK 127 million (77 million) · Reversals of reservations for credit losses amounted to SEK 16 million, for the corresponding period in 2021 reservations amounted to SEK 39 million. · Return on equity was 11.8 % (14.5 %) · The CET1 capital ratio was 16.3 % (16.0 %) Danske Hypotek’s covered bonds have the highest credit rating (AAA) from Standard

Biosergen completes the third cohort of BSG005 phase I trial

August 26, 2022: Biosergen AB (“Biosergen” or the “Company”) today announced that the Safety Review Committee has decided to continue the trial with cohort 4 in the Single Ascending Dose part of BSG005’s phase I trial.BSG005 is Biosergen’s lead development compound. It is a novel anti-fungal molecule from the group of polyene macrolides known for their broad anti-fungal and fungicidal effect, including on resistant and difficult-to-treat fungal strains, which make them unique within all antifungal drug classes.  The successful completion of the phase I trials will demonstrate, that BSG005

There are no items matching the current filter
There are no more items matching the current filter
Back to top